Amino Acid Transport Imaging of Breast Carcinoma via anti-3[18F] FACBC PET-CT: A Pilot Study

Breast cancer is the second most commonly diagnosed cancer in the world and the second leading cause of death among women. Mammography, breast ultrasound and MRI are commonly used imaging modalities in the detection, diagnosis, and treatment follow-up of breast cancer. In direct MRI comparisons, specificity is consistently lower than mammography and ultrasound in the detection of breast cancer. Mammography demonstrates lower sensitivities in younger population. Hence, there is currently a need for more sensitive and specific imaging modalities in the diagnosis and staging of breast carcinoma. Anti-1-amino-3-[18F]fluorocyclobutane-1-carboxylic acid (anti-3-[18F]FACBC) is a synthetic amino acid analog for positron emission tomography (PET), which has demonstrated promise for the staging and restaging of prostate carcinoma. Preliminary data suggesting that amino acid transport may be upregulated in breast carcinoma. We plan to perform a pilot study in 12 patients who have histologic confirmation of breast carcinoma or are about to undergo biopsy for suspected breast carcinoma, and who are also current therapy naïve. Patients will undergo anti-3-[18F] FACBC PET-CT per established techniques. Uptake within proven disease will be measured for this amino acid PET radiotracer, correlated to standard of care imaging, and validated to truth by histologic proof. Results of this pilot study may be used to design larger and more comprehensive studies examining clinical utility.

Funding Agency: Internal and Winship Cancer Institute Glenn Family Grant
PI: David M Schuster, MD

For further information about this study